142335-64-6

Basic information

• Product Name: 4-PYRROLIDIN-1-YLMETHYL-PHENYLAMINE
• Synonyms: AKOS MSC-0182;4-PYRROLIDIN-1-YLMETHYL-PHENYLAMINE;4-(PYRROLIDIN-1-YLMETHYL)ANILINE;4-(1-PYRROLIDINYLMETHYL)ANILINE;CHEMBRDG-BB 4011231;TIMTEC-BB SBB010602;4-(pyrrolidin-1-ylmethyl)aniline(SALTDATA: 2HCl 0.2H2O)
• CAS NO: 142335-64-6
• Molecular Formula: C₁₁H₁₆N₂
• Molecular Weight: 176.26
• Mol File: 142335-64-6.mol
• Article Data: 30

Chemical Properties

• Boiling Point: 290.681 °C at 760 mmHg
• Flash Point: 115.644 °C
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 0.00204mmHg at 25°C
• Refractive Index: 1.607
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-PYRROLIDIN-1-YLMETHYL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PYRROLIDIN-1-YLMETHYL-PHENYLAMINE(142335-64-6)
• EPA Substance Registry System: 4-PYRROLIDIN-1-YLMETHYL-PHENYLAMINE(142335-64-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 142335-64-6(Hazardous Substances Data)

Usage

General Description

4-Pyrrolidin-1-ylmethyl-phenylamine is a chemical compound that belongs to the class of phenylamines, which comprise a broad group of chemicals that includes pharmaceutical drugs and natural compounds. This specific compound is characterized by the presence of a phenylamine group and a pyrrolidinyl group. Although there is limited data available about its specific properties and uses, based on its structural similarities to other phenylamines, it is possible that it may possess properties such as basicity, lipophilicity, or reactivity. However, it should be noted that any potential use or application of this compound would require a thorough evaluation of its safety, toxicity, and environmental impact.

InChI:InChI=1/C11H16N2/c12-11-5-3-10(4-6-11)9-13-7-1-2-8-13/h3-6H,1-2,7-9,12H2

Upstream product

• 239074-27-2 4-(1,1-dimethylethoxycarbonylamino)benzylbromide 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 56302-41-1 4-carboxamidopyrrolidinophenyl-aniline 
• 123-75-1 pyrrolidine 
• 100-14-1 4-nitrobenzyl chloride 
• 133851-67-9 1-(4-nitro-benzyl)-pyrrolidine 

Downstream Products

• 945104-37-0 3-(4-tert-butylphenyl)-5,5-dimethyl-1-[(2-{[4-(pyrrolidin-1-ylmethyl)phenyl]amino}pyridin-4-yl)-methyl]imidazolidine-2,4-dione 
• 1022980-81-9 C₂₀H₁₉N₃O 
• 866956-98-1 [4-(pyrrolidin-1-ylmethyl)phenyl]amine hydrochloride 
• 72219-19-3 4-((pyrrolidin-1-yl)methyl)phenol 
• 1587623-04-8 N-(2-chloro-6-methylphenyl)-2-((2-methyl-6-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)pyrimidin-4-yl)amino)thiazole-5-carboxamide 
• 1567327-16-5 5,6-dimethoxy-2-(4-(pyrrolidin-1-ylmethyl)phenyl)benzo[d][1,2]selenazol-3(2H)-one 
• 1234201-99-0 3-(1H-indol-3-yl)-N-(4-(pyrrolidin-1-ylmethyl)phenyl)propanamide 
• 878106-29-7 2-(1H-indol-3-yl)-N-(4-(pyrrolidin-1-ylmethyl)phenyl)acetamide 
• 1234202-05-1 N-(2-(1H-indol-3-yl)ethyl)-4-(pyrrolidin-1-ylmethyl)aniline 
• 842965-59-7 C₁₃H₁₇ClN₂O 

Relevant articles and documents

SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA

Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.

INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF

Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

Beta-carboline derivative targeted to CDK and DNA and preparation method and medical application thereof

The invention discloses a beta-carboline derivative targeted to CDK and DNA and a preparation method and medical application thereof. The beta-carboline derivative has a structure shown in the general formula I in the description. The compound can be applied in combination with other antitumor drugs and can also be applied in combination with radiotherapy. The antitumor drugs or radiotherapy and the compound can be applied at the same time or at different times. The combined therapy can perform a synergistic effect, and thus the therapeutic effect can be easily improved.